evipedia.ai ← Back to Review

Audit: QRS - Melanotan II for Health & Longevity

Audit conducted on 06/08/2026 04:13 using AI4L / Opus 5

Iterations

Summary

Items Count
Total 91
Passed 81
Failed 0
N/A 10
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 Spot-checked across all populated spans: at-a-glance against ER Conclusion (lines 568–572), protocol cells against Therapeutic Protocol (lines 432–438), time-to-effect against Practical Considerations (line 487), benefit/risk tiers against the ER tier headings, gates against Key Interactions & Contraindications (lines 378–400), monitoring table against the ER biomarker table (lines 521–530), qualitative items against lines 534–542.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 The ER’s hedged items are carried at their ER tier (Speculative benefits and risks) rather than being asserted; no ER hedge is dropped in favour of a firmer statement.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Contraindication thresholds (140/90 mmHg, eGFR below 60, 90 days, 50 naevi, under 18) are preserved at ER strength; the ER’s “Absolute avoidance in combination” for ultraviolet exposure is carried in the STOP gate rather than the caution gate.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Benefits come only from Expected Benefits, risks only from Potential Risks & Side Effects, gates only from Key Interactions & Contraindications, monitoring and qualitative items only from Monitoring Protocol & Defining Success. No Benefit- or Risk-Modifying Factor is surfaced anywhere.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 The QRS contains no PMIDs, no NCT identifiers, no author names and no brand names.
1.6 The QRS does not introduce new attributions. 🟢 No attributions of any kind appear in the QRS.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 The ER’s measured, sceptical framing (“The pharmacology is genuine; the evidence is thin on both sides, the supply is unverifiable”) is mirrored in the at-a-glance and in the tier distribution.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Quantified targets, explicit decision gates and a defined monitoring cadence give the reader the means to act; the register is factual rather than alarmist.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Content is stated as observed practice and observed evidence (“Evening, 1–2 h before sleep”, “Loading 2–4 weeks”), not as instructions issued to a patient.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No imperative or prescriptive verbs in the QRS voice; the monitoring targets are presented as ranges drawn from the ER table.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 No occurrence of “recommend”, “advise”, “should”, or “we suggest” in the QRS body.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person pronouns appear anywhere in the populated spans.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms retained (rhabdomyolysis, melanonychia, eGFR, HOMA-IR) are the ER’s own biomarker and risk names, where no plain-language equivalent exists without loss.
2.8 Information is presented in a concise and very compact manner 🟢 Every gate item, benefit, risk and monitoring cell is a single short phrase; no sentence exceeds one line of the rendered card.
2.9 It DOES NOT address the reader directly 🟢 Confirmed — no direct address in any span.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 The sheet assumes willingness to obtain dermoscopic mapping, home blood-pressure measurement and a multi-analyte laboratory panel.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 The monitoring cadence (twice-daily blood pressure for two weeks, laboratory testing at three timepoints, dermatological review over three years) presumes exactly that willingness.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Nothing is simplified to a general-population “ask your doctor” register; the sheet retains genotype, phototype and biomarker specificity.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 The at-a-glance foregrounds the surveillance-blindness and supply-quality problems, which is the longevity-relevant weighting, rather than the cosmetic tanning appeal.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 The string “anti-aging” does not appear anywhere in the QRS.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 “Subcutaneous injection”, “priapism”, “sympathomimetics”, “posterior reversible encephalopathy syndrome” and similar are used throughout; the plain-language wording is confined to the at-a-glance, where item 7.4 requires it.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All fixed strings verified byte-identical to [qrs_template]: lines 445, 490, 532, 599, 630, 744 (headings), 558 and 577 (gate headings), 536/541/544/548 and 603/609/615/621 (tier labels), 634–636 (column headers).
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All template variable names are present: page_title, header_topic, header_subline_date, header_subline_model, at_a_glance, action_1–3 label/value/sub, time_1–3 label/value/sub, benefits_high/medium/low/speculative, stop_items, caution_items, risks_high/medium/low/speculative, marker_#name/target/why (expanded to 8 rows), monitoring_cadence, qualitative_item# (expanded to 9 items). 67 spans in total.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 A byte diff of lines 1–409 against [qrs_template] shows differences only in the frontmatter values and the <title> text; the non-variable spans website="evidence_review", website="audit" and website="full_review" are unchanged, as is the footer disclaimer.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No source ER section that feeds the QRS is empty; every benefit tier, risk tier, gate list and monitoring group is populated in the ER.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol cell labels “The gray-market community regimen”, “Route and reconstitution” and “Best time of day” reproduce the ER bold labels at lines 434, 436 and 438 verbatim; monitoring row labels reproduce the ER Biomarker column verbatim.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 No invented labels; the eight monitoring markers carry the ER’s exact biomarker names including “Creatine kinase (CK)”, “Fasting insulin and HOMA-IR” and “Total and free testosterone (men)”.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 A Unicode scan of the file returns no emoji codepoints; the ER’s 🟩/🟥/🟨/⚠️ markers were correctly dropped in favour of the template’s CSS tiering.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Every section is condensed to the shortest form the completeness requirements of items 8.2, 14.2 and 15.2 permit — single-phrase gate items, tier lines with no qualifiers, three-to-five-word monitoring rationales — rather than being carried over at ER length.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Lines 2–14: the comment opens immediately after <!doctype html> on line 1 and closes before the “blank template” comment on line 16.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 Opening --- on line 3, closing --- on line 13; the preamble text “QRS — Metadata (invisible, parsed by audit tooling)” sits on line 2, before the opening delimiter.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 The block sits inside an HTML comment and none of its values are echoed by any visible element.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration: "00:03" is quoted, correctly, because it contains a colon; all other values are bare and untrimmed of nothing.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 Line 4: er_filename: melanotan_ii_2026-0806-0009_Opus_ER.md.
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 Line 6: qrs_creation_date: 2026-0806-0229, correctly formatted.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 Line 7: qrs_creator_ai_nickname: Opus.
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 “Opus” is a single word with no version or qualifier.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 Line 8: qrs_creator_ai_fullname: Opus 5.
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 5” is nickname plus version number with no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 Line 9: qrs_filename: melanotan_ii_2026-0806-0009_Opus_QRS.html, matching the file on disk.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Re-verified across all nine keys; only the colon-bearing duration value is quoted.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 Line 22: Melanotan II for Health &amp; Longevity - Quick Reference Sheet, matching ER frontmatter canonical_topic with the ampersand entity-encoded.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 Line 417: Melanotan II for Health &amp; Longevity.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 Line 421: 08/06/2026, the correct MM/DD/YYYY rendering of qrs_creation_date 2026-0806-0229.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 Line 425: Opus 5, matching the frontmatter value.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 The header block (lines 415–428) contains only the title and the template’s fixed subline; the ER’s “Also known as” line was correctly not carried over.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Lines 434–437 compress all three Conclusion paragraphs into one passage: origin and pigment effect, sexual effects in men, the harm cluster, and the supply-quality problem.
7.2 [at_a_glance] is no longer than 60 words 🟢 55 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 “laboratory-made copy of the body’s own pigment signal” (ER line 568), “darkens skin reliably” (line 568), “triggers erections and raises sexual desire” (line 568), “near-universal nausea, unwanted erections, rising blood pressure” (line 570), “moles that darken and multiply” plus loss of the early skin-cancer signal (line 570), “Nothing sold is made to any quality standard” (line 570).
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 No acronyms; “moles”, “skin cancer”, “blood pressure”, “pigment signal” are all terms a non-specialist would use unprompted.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial names, years, sample sizes or p-values appear.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No numbers of any kind appear in the at-a-glance.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All twelve items trace to ER lines 396 and 400.
8.2 [stop_items] represent the Contraindications from the ER 🟢 All eleven populations from ER line 400 are present in order, plus the ER’s “Absolute avoidance in combination” ultraviolet/sunbed item from line 396, which is a hard stop rather than a caution.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Lines 561–572: twelve discrete <li> elements inside the stop_items span.
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 No dashes introducing trailing clauses; the ER’s parenthetical glosses (“a pattern of many irregular moles carrying elevated melanoma risk”, “a calculated measure of kidney filtering capacity”) and the mitigating-action sentences were all stripped.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 “(above 140/90 mmHg)”, “within 90 days”, “(eGFR below 60)”, “More than 50”, “Fitzpatrick type I with blistering sunburn” and “Under 18 years of age” all retain the ER’s decision-relevant thresholds.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER’s contraindication bullet uses no ranking notation inside parentheses.
8.7 If no [stop_items] are present the section is left empty N/A Twelve stop items are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All ten items map one-to-one to ER bullets at lines 378–398.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 The ten interaction bullets are carried; the ultraviolet/sunbed bullet is correctly not duplicated here, having been placed in the Contraindications gate.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Lines 580–589: ten discrete <li> elements inside the caution_items span.
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Every “Mitigating action:” clause and every mechanistic explanation from the ER bullets was stripped; no trailing dash clauses remain.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Each item retains a named exemplar drug list, trimmed to fit: sildenafil/tadalafil, tamsulosin, nitroglycerin, amlodipine/metoprolol, amphetamine, trazodone, pseudoephedrine/ibuprofen, yohimbine, synephrine, copper/tyrosine, semaglutide/tirzepatide. None is dropped entirely.
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER’s interaction bullets use no ranking notation inside parentheses; the parenthetical drug lists are already plain comma-separated.
9.7 If no [caution_items] are present the section is left empty N/A Ten caution items are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 All three cells trace to the ER Therapeutic Protocol section, lines 432–438.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Dose regimen, route and reconstitution, and timing of administration are the three decision-bearing aspects; the remaining ER bullets (half-life, split dosing, genotype, sex, age, baseline biomarkers) are modifiers rather than implementation steps.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER provides more than three actionable implementation aspects; all three sets are used.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All nine spans populated: the dose cell carries both the community range and the published trial dose of 0.025 mg/kg (ER lines 432, 434); the route cell carries bacteriostatic-water reconstitution, abdominal/thigh sites and the intranasal variability caveat (line 436); the timing cell carries the 1–2 hour pre-sleep window and the 1–5 hour peak-effect rationale (line 438).

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Skin pigmentation, erectile response and appetite reduction — exactly the three effects enumerated in the ER Practical Considerations “Time to effect” bullet, line 487.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Pigmentation and erection are the two ER High-tier benefits and lead; appetite reduction is a Low-tier benefit and is placed last.
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three distinct time-to-effect aspects are present in the ER; all three sets are used.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 “1–2 weeks / Plateaus at 3–4 weeks”, “1–5 hours / After a single dose”, “Immediate / Not reliably separable from early nausea” all reproduce ER line 487.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides explicit time-to-effect information, so the section is correctly retained.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 All eight entries map to the ER Expected Benefits sub-headings at lines 158, 165, 175, 185, 192, 202, 207 and 212.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four spans present and populated at lines 534, 540, 543 and 546.
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Each ER sub-heading is reduced to a noun phrase; none of the ER’s Magnitude figures (38.0 vs 3.0 minutes, 68% vs 19%, p < 0.01) is carried.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses appear in any of the four benefit tier lines.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four ER benefit tiers contain items, so no span needed hiding.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 All sixteen entries map to the ER sub-headings at lines 242, 249, 256, 263, 270, 280, 287, 294, 301, 311, 318, 325, 332, 339, 349 and 354.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four spans present and populated at lines 601, 607, 613 and 619.
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Each ER sub-heading is reduced to a short noun phrase; the ER’s Magnitude figures (12.9%, 151/85 mmHg, CK 17,773 IU/L, 4.32–8.84 mg) are all absent.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses appear in any of the four risk tier lines.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four ER risk tiers contain items, so no span needed hiding.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 The table reproduces the ER Monitoring Protocol & Defining Success biomarker table, lines 521–530, in the same order.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All eight ER biomarkers present: mapped naevus count and dermoscopy, resting blood pressure, resting heart rate, creatine kinase, serum creatinine and eGFR, fasting insulin and HOMA-IR, 25-hydroxyvitamin D, and total and free testosterone. Targets match the ER’s Optimal Functional Range column.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Line 738 reproduces the ER cadence from lines 517 and 519: blood pressure pre- and 2 h post-dose daily for two weeks then weekly, laboratory testing at baseline/4/12 weeks, dermatological review at 3 months then every 6–12 months for at least three years after the last dose.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 All nine items map to the ER qualitative marker list at lines 534–542.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All nine ER qualitative markers present in ER order: pigmentation evenness, new or changing pigmented lesions, nail pigment bands, nausea severity and trajectory, appetite and protein intake, libido and erectile function, sleep quality, next-day energy/restlessness/anxiety, and skin oiliness and acne.

Issues 06/08/2026 04:13

Pass rate 100.00%. No issues found.

Issues 06/08/2026 04:07

  1. 2.15 — Colloquial “if” for “whether”: marker_8_why (QRS line 731) reads “Establishes if an erectile complaint is hormonal”, replacing the ER’s formal “Establishes whether an erectile complaint is hormonal” (ER line 530).

Fixes 06/08/2026 04:07

  1. 2.15 — Formal wording in monitoring rationale: Changed marker_8_why from “Establishes if an erectile complaint is hormonal” to “Establishes whether an erectile complaint is hormonal”, matching the ER’s formal phrasing.

Issues 06/08/2026 03:58

  1. 4.3 — Over-the-counter label truncated: The Key Interactions item at line 585 reads “Over-the-counter (pseudoephedrine, ibuprofen)”, abbreviating the ER’s bold label “Over-the-counter medications” (ER line 388) to a dangling adjective with no noun.
  2. 1.1 — Testosterone target missing unit: [marker_8_target] at line 727 reads “Total 600–900; free 15–25 ng/dL”, omitting the ng/dL unit the ER states for total testosterone (ER line 530: “Total 600–900 ng/dL; free 15–25 ng/dL”).

Fixes 06/08/2026 03:58

  1. 4.3 — Over-the-counter label restored: Changed the Key Interactions item from “Over-the-counter (pseudoephedrine, ibuprofen)” to “Over-the-counter medications (pseudoephedrine, ibuprofen)”, matching the ER’s bold label.
  2. 1.1 — Testosterone target unit added: Changed [marker_8_target] from “Total 600–900; free 15–25 ng/dL” to “Total 600–900 ng/dL; free 15–25 ng/dL”, restoring the unit the ER states for total testosterone.

Issues 06/08/2026 03:51

  1. 4.2 / 4.3 — Invented protocol cell label: action_1_label (line 449) is “Dose”, which is not a bold label anywhere in the ER Therapeutic Protocol section; the cell’s content comes from the “The gray-market community regimen:” bullet (ER 434), while the two adjacent cells do use ER labels verbatim.
  2. 2.15 — Colloquial “labs” in cadence: monitoring_cadence (line 738) writes “labs at baseline, 4 and 12 weeks”; the ER’s own formal term is “laboratory testing” (ER 519).

Fixes 06/08/2026 03:51

  1. 4.2 / 4.3 — Invented protocol cell label: action_1_label changed from the invented “Dose” to the ER’s verbatim bold label “The gray-market community regimen”; action_1_sub now reads “Published trial dose 0.025 mg/kg” so the contrasting regimen is explicitly attributed.
  2. 2.15 — Colloquial “labs” in cadence: monitoring_cadence changed from “labs at baseline, 4 and 12 weeks” to “laboratory testing at baseline, 4 and 12 weeks”, matching the ER’s formal term.

Issues 06/08/2026 03:41

  1. 1.3 — Surveillance duration softened: [monitoring_cadence] (QRS line 738) says dermatological review “every 6–12 months for three years after the last dose”, dropping the ER’s “for at least three years” (ER line 519) and converting a minimum into a fixed endpoint.
  2. 8.5 — Sickle cell trait dropped from gate: The contraindication at QRS line 568 reads “Sickle cell or priapism-predisposing conditions”, losing the ER’s “sickle cell disease or trait” (ER line 400) — the severity class that brings trait carriers inside the gate.

Fixes 06/08/2026 03:41

  1. 1.3 — Surveillance duration restored: [monitoring_cadence] changed from “every 6–12 months for three years after the last dose” to “every 6–12 months for at least three years after the last dose”, matching the ER’s minimum-duration phrasing.
  2. 8.5 — Sickle cell trait restored to gate: The contraindication item was changed from “Sickle cell or priapism-predisposing conditions” to “Sickle cell disease or trait, or priapism-predisposing conditions”.

Issues 06/08/2026 03:37

  1. 4.5 — Sheet exceeds one A4 page: Estimated rendered height is roughly 1.9 A4 pages; the two decision gates (QRS lines 560–590, most of the 22 items wrapping to two lines in a half-width column), the 232-character cadence sentence (line 738) and the two-line Monitoring targets (lines 689–690, 702–703, 726–727) are the sections over budget.
  2. 4.2 / 4.3 — Protocol labels not ER-verbatim: action_2_label “Route” (line 463) abbreviates the ER bold label “Route and reconstitution” (ER line 436) and action_3_label “Timing” (line 477) paraphrases “Best time of day” (ER line 438).

Fixes 06/08/2026 03:37

  1. 4.2 / 4.3 — Protocol labels restored to ER wording: action_2_label changed from “Route” to the ER’s bold label “Route and reconstitution”, and action_3_label from “Timing” to “Best time of day”.
  2. 4.5 — Contraindication items condensed: Shortened the first, second and fourth stop items (e.g. “Personal history of melanoma or dysplastic naevus syndrome” → “Personal melanoma or dysplastic naevus syndrome”) so each now occupies a single line in the half-width gate.
  3. 4.5 — Key Interaction items condensed: Shortened eight caution items (e.g. “Supplements with additive sympathetic or thermogenic effect (synephrine)” → “Thermogenic supplements (synephrine)”), keeping at least one example drug per class as required by 9.5.
  4. 4.5 — Monitoring targets and cadence condensed: Trimmed the creatinine/eGFR, insulin/HOMA-IR and testosterone targets and the marker 8 “Why” cell to one line each, and cut the cadence sentence from 232 to 199 characters.
  5. 4.5 — Benefits and Protocol cells condensed: Shortened the speculative benefits line to one rendered line and tightened the dose and route sub-cells.

Issues 06/08/2026 03:29

  1. 2.15 — Non-standard term “erectile loss”: [marker_8_why] (line 731) reads “Establishes whether erectile loss is hormonal”; the ER (line 530) uses “an erectile complaint”, and the QRS itself uses the formal term “erectile dysfunction” in [benefits_high].

Fixes 06/08/2026 03:29

  1. 2.15 — Non-standard term “erectile loss”: Changed [marker_8_why] from “Establishes whether erectile loss is hormonal” to “Establishes whether an erectile complaint is hormonal”, matching the ER’s formal wording.

Issues 06/08/2026 03:21

  1. 1.1 — Contraindication drops “history of”: The stop item “Fitzpatrick type I with blistering sunburn” (QRS line 564) is not literally supported by the ER, which reads “Fitzpatrick skin type I with a history of blistering sunburn” (ER line 400); the omission converts a past-history gate into a present-state one.
  2. 4.3 — Interaction label abbreviated: The caution item “Supplements with additive thermogenic effect” (QRS line 587) abbreviates the ER bold label “Supplements with additive sympathetic or thermogenic effect” (ER line 392), dropping the sympathetic/pressor half of the hazard that the ER identifies as the clinical consequence.

Fixes 06/08/2026 03:21

  1. 1.1 — Restored “history of” in contraindication: Changed the stop item from “Fitzpatrick type I with blistering sunburn” to “Fitzpatrick type I with history of blistering sunburn”, matching the ER’s past-history gate.
  2. 4.3 — Restored full interaction label: Changed “Supplements with additive thermogenic effect (synephrine)” to “Supplements with additive sympathetic or thermogenic effect (synephrine)”, reinstating the ER’s bold label wording.

Issues 06/08/2026 03:11

  1. 1.3 / 8.5 — Contraindication qualifiers dropped: Line 560 states “dysplastic naevi” where the ER (line 400) specifies “dysplastic naevus syndrome”, and line 561 states “Family history of melanoma” where the ER specifies “a first-degree relative with melanoma”; both broaden the gate beyond the ER.
  2. 8.5 — PRES truncated to a non-entity: Line 568 reads “Prior priapism or encephalopathy syndrome”, truncating the ER’s “posterior reversible encephalopathy syndrome” (line 400) to a term that names no condition.
  3. 1.1 — Maintenance dosing frequency altered: [action_1_sub] (line 456) states “then 250–1,000 µg weekly” whereas the ER Therapeutic Protocol (line 434) specifies “250–1,000 µg once or twice weekly”.
  4. 1.3 — Appetite/nausea hedge removed: [time_3_sub] (line 523) states “Not separable from early nausea”; the ER (line 487) says the appetite effect “is not reliably separable from nausea in the first days”.

Fixes 06/08/2026 03:11

  1. 1.3 / 8.5 — Contraindication qualifiers restored: Changed “Personal history of melanoma or dysplastic naevi” to “…or dysplastic naevus syndrome” and “Family history of melanoma, or CDKN2A mutation” to “First-degree relative with melanoma, or CDKN2A mutation”, matching the ER gate exactly.
  2. 8.5 — PRES named in full: Replaced “Prior priapism or encephalopathy syndrome” with “Prior priapism or posterior reversible encephalopathy syndrome”.
  3. 1.1 — Maintenance dosing frequency corrected: [action_1_sub] now reads “then 250–1,000 µg once or twice weekly” instead of “then 250–1,000 µg weekly”, matching the ER Therapeutic Protocol.
  4. 1.3 — Appetite/nausea hedge restored: [time_3_sub] changed from “Not separable from early nausea.” to “Not reliably separable from early nausea.”

Issues 06/08/2026 03:02

  1. 4.5 — Sheet overflows one A4 page: At the stylesheet’s own print geometry (A4, @page margin 0, .sheet padding 12mm → a 703 × 1032 px content box) the populated sheet renders to roughly 2,200 px, about 2.1 pages; the Key Interactions gate (~470 px), Monitoring table (~345 px) and Qualitative Assessment (~240 px) alone exhaust the available height. The discretionary-length variables were left at ER length instead of being condensed to the per-section budget — notably action_2_sub (180 characters wrapping to 5 lines in a 218 px column, QRS 469–473), caution_items 4, 6, 7 and 8 (107–157 characters each, QRS 597–616), and several stop_items carrying full ER phrasing (QRS 572–580).

Fixes 06/08/2026 03:02

  1. 4.5 — Protocol cell subtexts condensed: action_1_sub, action_2_sub and action_3_sub were cut from 125–180 characters to 65–83 characters each (e.g. “Lyophilized powder reconstituted with bacteriostatic water, into abdominal or thigh tissue. Intranasal preparations deliver an unknown and highly variable fraction of the stated dose.” → “Powder in bacteriostatic water, abdominal or thigh. Intranasal delivery highly variable.”), taking each cell from 4–5 wrapped lines to 2.
  2. 4.5 — Time-to-effect subtexts reduced to one line: time_1_sub, time_2_sub and time_3_sub were shortened to “Plateaus at 3–4 weeks.”, “After a single dose.” and “Not separable from early nausea.”, halving the Time to effect row height.
  3. 4.5 — Benefits tiers cut to four lines: benefits_high and benefits_speculative were trimmed to their bare facts (“Skin pigmentation without ultraviolet exposure; erection in men with erectile dysfunction”; “Improved insulin sensitivity; neuroprotective and cognitive effects; vitiligo repigmentation”), and benefits_low shortened to a single line.
  4. 4.5 — Risk tiers condensed: risks_high was reduced from 210 to 96 characters (“Nausea; spontaneous erections; somnolence; mole darkening and eruption; adulterated product”) and risks_medium, risks_low and risks_speculative were tightened, with all fourteen ER risk entries retained.
  5. 4.5 — Contraindications shortened to one line each: Eleven of the twelve stop_items were trimmed to fit a single gate line (e.g. “Chronic kidney disease (eGFR below 60 mL/min/1.73 m²)” → “Chronic kidney disease (eGFR below 60)”), reducing the gate from 19 wrapped lines to 12 while keeping every threshold and time window.
  6. 4.5 — Key Interaction example lists trimmed: Each caution_item now carries one or two representative example drugs instead of the full ER list (e.g. “Stimulants and sympathomimetics (amphetamine, methylphenidate, cocaine, pseudoephedrine, high-dose caffeine)” → “Stimulants and sympathomimetics (amphetamine, cocaine)”), cutting the gate from 25 wrapped lines to 12 with no example list dropped entirely.
  7. 4.5 — Monitoring “Why” column reduced to one line per row: All eight marker_#_why values were condensed (e.g. “A pharmacological tan makes no vitamin D, and darker skin then reduces synthesis from sun exposure” → “A pharmacological tan makes no vitamin D”), and marker_1_target shortened to “No new or evolving lesions”, taking most table rows from two lines to one.
  8. 4.5 — Monitoring cadence tightened: monitoring_cadence was shortened from 238 to 222 characters by dropping the redundant “mapped” qualifier before “dermatological review”, bringing it to two wrapped lines.

Issues 06/08/2026 02:51

  1. 4.2 / 4.3 — Interaction labels paraphrased: Six caution_items labels rewrite the ER’s bold labels: “Antihypertensives” (line 595), “Drugs associated with priapism” (line 601), “Erectogenic supplements” (line 608), “Sympathetic or thermogenic supplements” (line 612), “Supplements affecting pigmentation” (line 615) and “other appetite suppressants” (line 617). Dropping “independently” and “or melanocytes” also narrows the meaning of two of them.
  2. 1.1 — Intranasal claim not ER-supported: action_2_sub (line 470) says “Intranasal delivery is unknown and highly variable”, whereas the ER (line 436) says intranasal preparations “deliver an unknown and highly variable fraction of the stated dose”.

Fixes 06/08/2026 02:51

  1. 4.2 / 4.3 — Interaction labels restored verbatim: Six caution_items labels were reverted to the ER’s bold labels: “Antihypertensives” → “Antihypertensive medications”, “Drugs associated with priapism” → “Drugs independently associated with priapism”, “Erectogenic supplements” → “Supplements with additive erectogenic effect”, “Sympathetic or thermogenic supplements” → “Supplements with additive sympathetic or thermogenic effect”, “Supplements affecting pigmentation” → “Supplements affecting pigmentation or melanocytes”, and “other appetite suppressants” → “other appetite-suppressing agents”. The thermogenic entry also regained the ER’s “high-dose” qualifier on green tea extract.
  2. 1.1 — Intranasal claim aligned with ER: action_2_sub was changed from “Intranasal delivery is unknown and highly variable” to “Intranasal preparations deliver an unknown and highly variable fraction of the stated dose”, matching the ER’s Therapeutic Protocol wording.

Issues 06/08/2026 02:43

  1. 4.5 — One-page budget exceeded: The QRS carries roughly 6,600 characters of visible body text, about twice a single A4 page, because the Protocol sub-lines (lines 456–458, 471–473, 486–488), the eight Monitoring “Why” cells (lines 687–790), the cadence line (lines 799–802) and the nine Qualitative Assessment items (lines 812–861) reproduce ER prose near-verbatim instead of being condensed to the per-section budget.

Fixes 06/08/2026 02:43

  1. 4.5 — Protocol and time-to-effect sub-lines condensed: Rewrote all three action_#_sub and two time_#_sub strings to drop restated framing (e.g. “Evening dosing is near-universal in practice for both approaches, because …” → “Near-universal in practice, because …”), cutting the Protocol panel from 997 to 799 characters.
  2. 4.5 — Monitoring rationale and cadence condensed: Tightened seven of the eight marker_#_why cells (e.g. “Detects the compound’s characteristic melanocytic changes and preserves melanoma surveillance” → “Detects melanocytic change and preserves melanoma surveillance”) and shortened monitoring_cadence, cutting the Monitoring card from 1,457 to 1,298 characters with all eight biomarkers and their optimal ranges retained.
  3. 4.5 — Qualitative Assessment items condensed: Reworded five of the nine qualitative_item_# entries away from near-verbatim ER prose (e.g. “Evenness and distribution of pigmentation, particularly whether darkening is concentrating in existing moles and freckles rather than spreading uniformly” → “Evenness of pigmentation, and whether darkening concentrates in existing moles and freckles”), cutting the card from 909 to 779 characters with all nine markers retained.
  4. 4.5 — Decision gate items tightened: Trimmed redundant articles and prefixes across the Contraindications and Key Interactions lists (e.g. “Supplements with additive erectogenic effect (…)” → “Erectogenic supplements (…)”, “Uncontrolled hypertension (above 140/90 mmHg on repeated measurement)” → “Uncontrolled hypertension (above 140/90 mmHg)”), cutting the gates from 1,794 to 1,642 characters while keeping all twelve stop items, all ten caution items and every threshold and named example drug.

Note: visible body text fell from 6,631 to 5,992 characters. The remaining length is set by items 8.2, 9.2, 14.2 and 15.2, which require every ER contraindication, key interaction, measurable biomarker and qualitative marker to be listed; further reduction would have to drop mandated items.

Issues 06/08/2026 02:35

  1. 1.1 — Dangling “near-universal” attribution: [action_3_sub] (QRS line 486) reads “Near-universal in practice for both approaches: nausea, flushing, somnolence, yawning and spontaneous erection all peak in the 1–5 hour window”, which attaches “near-universal in practice” to the symptom list; the ER (line 438) applies that phrase to evening dosing, not to the symptoms.
  2. 12.3 — Redundant “(conflicted)” qualifier: [benefits_low] (QRS line 555) appends “(conflicted)” to “photoprotection from increased eumelanin”; the tier label already encodes evidence strength, so the qualifier is redundant detail that item 12.3 excludes.
  3. 13.3 — Redundant “(conflicted)” qualifier: [risks_medium] (QRS line 646) appends “(conflicted)” to “Melanoma”; the tier label already encodes evidence strength, so the qualifier is redundant detail that item 13.3 excludes.

Fixes 06/08/2026 02:35

  1. 1.1 — Dangling “near-universal” attribution: Rewrote [action_3_sub] from “Near-universal in practice for both approaches: nausea, flushing, … all peak in the 1–5 hour window” to “Evening dosing is near-universal in practice for both approaches, because nausea, flushing, … all peak in the 1–5 hour window after administration”, so the phrase attaches to evening dosing as in the ER.
  2. 12.3 — Redundant “(conflicted)” qualifier: Removed “(conflicted)” from [benefits_low], leaving “photoprotection from increased eumelanin”.
  3. 13.3 — Redundant “(conflicted)” qualifier: Removed “(conflicted)” from [risks_medium], leaving “Melanoma”.